Subscribe Now
Forgot Password?

Weekly News, Analysis, and Commentary

Company News Feature

SpineJack / Courtesy of Vexim

VEXIM Completes Enrollment of Major Clinical Trial

Elizabeth Hofheinz, M.P.H., M.Ed. • Tue, March 7th, 2017

Print this article

Vexim is announcing the completion the enrollment of a major trial. According to the company, it is a multicenter European study that will support a 510(k) submission to the FDA.

According to the February 21, 2017 news release, the prospective and randomized multicenter study “…aims to compare safety and efficacy of the SpineJack vs balloon kyphoplasty on 152 patients with osteoporotic vertebral compression fractures. It is being conducted in 12 centers in Germany, France, Italy, Spain and Switzerland…”

“Vexim’s clinical trial compares improvements in terms of back pain, functional and physical capability, quality of life, device safety, analgesic usage and vertebral height restoration, on patients suffering osteoporotic vertebral compression fractures and treated with the SpineJack and balloon kyphoplasty. Trial's success will be defined by showing the SpineJack's non-inferiority to balloon kyphoplasty on a primary endpoint which is a composite measure of pain reduction, maintenance or improvement in function and absence of device related serious adverse event.”

“As of today, all 152 patients planned have been randomized. Half of them within SpineJack treatment group, the other half in the balloon kyphoplasty group. The finalization of patient enrollment represents an important milestone in the trial's schedule. SpineJack 510(k) file is planned to be submitted to the FDA before the end of year 2017.”

CEO Vincent Gardès told OTW, “This is an important milestone since it creates for the company a clear timeline for the end of the patients follow up period and preparation for our 510(k) filing which will occur at the end of 2017. It also gets Vexim closer to the launch of the SpineJack in the United States of America which is planned beginning of 2018 provided Spinejack gets its regulatory approval by the FDA. Last but not least, this is also a great achievement for a startup company to run an international, randomized and multicenter clinical study of this size and importance (12 sites, 152 patients, 5 countries).”

“The next six months will be dedicated to the collection of all clinical reports and documents while planning the follow up visits with the patients. We will also work on the 510(k) filing that we plan to submit together with the final clinical data and report at the beginning of Q4 2017.”

Send to a Friend

The article link will be sent to the email address you provide

Your Name (required)

Your Email (required)

Friend's Email (required)


Leave a Reply


Email Address (will not be published)